Early phase trials of TNFerade gave encouraging results with melanoma [95], but a phase III trial recently found no survival benefit in patients with pancreatic cancer [96] and it was not established whether the radiation inducible promoter in that non-replicating (and therefore not strictly oncolytic) virus actually led to significant TNF expression in patients. This evidence concerns the gene TNF and melanoma.